## DO/EO WORKSHEET

U.S. Appl. No. 10/552, 303

Paralegal/ National Stage Division

(	J.S. Appl. No. 10/352, 503 International Appl. No. 48204/01/805
•	Application filed by: 20 months 30 months
Γ	WIPO PUBLICATION INFORMATION:
	Publication No.: WO 2004 1092 170 Publication Language: DEnglish O German D Jananese O Chinese D Kossey
	Publication Date: 28 Octof
<u> </u>	Not Published: U.S. only designated DEP request Published: DEP reque
	International Application (RECORD COPY)
	Article 19 Amendments Request form PCT/RO/101
1	The state of the s
	US OFR OCH OES ORU OAT OKR O OUS OFR OCH OES ORU OAT OKR OTHER
	PCT/IPEA/409 IPER was NOT AVAILABLE at the time of INONE DATABLE At the time of INONE
	Annexes to 409
	Priority Document (s) No. / Other:
	RECEIPTS FROM THE APPLICANT (other than checked above)
	Basic National Fee (or authorization to charge) Preliminary Amendment(s) Filed on :
5	Description Claims Abstract Information Disclosure Statement(s) Filed on :
	Assignment Document (forwarded to
	Drawing Figure(s) - (# of drwgs. O ) Assignment Branch)
	Assignee PG Publication Notice
1	☐ entered ☐ not entered : ☐ Substitute Specification Filed on :
ı	on of a page for page substitution 1
	Annexes to 409
	☐ entered ☐ not entered : ☐ Oath/Declaration (executed)
Į.	O not a page for page substitution O unsigned O no citizenship O no translation O other: ONA Diskette O Sequence Listing
	Application Data Sheet
	Power of Attorney/ Change of Address
	OTES:
	2 130 330 23 Specification Control
35 U.	S.C. 371 - Receipt of Request (PTO-1390)
Date.	Acceptable Oath/ Declaration Received
Date	of Completion of requirements under 35 U.S.C. 371
Date	of Completion of ALL requirements
ľ	of Completion of DO/ EO 903 - Notification of Acceptance
l	of Completion of DO/ EO 905 - Notification of Missing Requirements
	f Completion of DO/ EO 909 - Notification of Abandonment
	f Completion of DO/ EO 916 - Notification of Defective Response
Date of Completion of DO/ EO 922 - Notification to Comply w/ Requirements for Patent  Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures	
	Complete Control Contr